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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.017Yes-associated protein (YAP) is a transcriptional co-activator of hippo signaling pathway, which plays an
important role in organ size control and tumorigenesis. Here we report that YAP and its downstream
transcriptional targets CCN1 and CCN2 are markedly elevated in keratinocytes in human skin basal cell
carcinoma tumor islands. In human keratinocytes, knockdown of YAP signiﬁcantly reduced expression of
CCN1 and CCN2, and repressed proliferation and survival. This inhibition of proliferation and survival was
rescued by restoration of CCN1 expression, but not by CCN2 expression. In basal cell carcinoma stroma,
CCN2-regulated genes type I collagen, ﬁbronectin, and a-smooth muscle actin were highly expressed.
Furthermore, atomic force microscopy revealed increased tissue stiffness in basal cell carcinoma stroma
compared to normal dermis. These data provide evidence that up-regulation of YAP in basal cell carcinoma
impacts both aberrant keratinocyte proliferation, via CCN1, and tumor stroma cell activation and stroma
remodeling, via CCN2. Targeting YAP and/or CCN1 and CCN2 may provide clinical beneﬁt in basal cell
carcinoma. (Am J Pathol 2014, 184: 937e943; http://dx.doi.org/10.1016/j.ajpath.2013.12.017)Supported by NIH grants RO1 ES014697 (T.Q.), 3R01ES014697-03S1
(T.Q.), and RO1AG031452 ( G.J.F.).
Disclosures: None declared.Yes-associated protein (YAP) is a major downstream
effector of the hippo signaling pathway, which was origi-
nally recognized as a vital regulator of organ size in ani-
mals.1,2 YAP activity is primarily regulated by subcellular
localization, which is responsive to cell-cell interactions
through the hippo pathway3 or mechanical forces through
unknown mechanisms.4 Phosphorylation of YAP sequesters
it in the cytoplasm and consequently inhibits YAP nuclear
translocation and function as a transcriptional co-activator.
Recently, YAP was identiﬁed as an oncogene in various
human cancers.3,5,6 Enhanced expression of YAP has been
reported in solid tumors, such as colon adenocarcinoma,
lung adenocarcinoma, ovarian serous cystadenocarcinoma,
and medulloblastoma.6,7 However, the expression of YAP
in human skin cancer has not been studied.
Cysteine-rich protein 61, connective tissue growth factor,
nephroblastoma overexpressed (CCN) family membersstigative Pathology.
.cysteine-rich protein 61 (CCN1) and connective tissue
growth factor (CCN2) have emerged as direct transcriptional
targets of YAP.7e9 Members of the CCN family of proteins
exhibit diverse cellular functions, such as regulation of cell
proliferation, chemotaxis, apoptosis, adhesion, motility, ion
transport, and extracellular matrix (ECM) production.10e12
CCN proteins are secreted and associate with the ECM in
connective tissue.13,14 YAP up-regulation of CCN1 has been
implicated in proliferation and survival of mouse keratino-
cytes.8 However, the role of CCN1 and CCN2 in the onco-
genic actions of YAP is poorly understood.
Recently, increased nuclear localization of YAP has been
shown to be linked to cutaneous squamous cell carcinoma-like
Quan et altumors in transgenic mice.15 Nuclear localization of YAP is
regulated in part by a-catenin, which acts as a tumor sup-
pressor by retaining YAP in the cytoplasm, thereby limiting
proliferation of epidermal stem/progenitor cells.16 Cutaneous
basal cell carcinoma (BCC) is the most common form of
human cancer, with incidence estimated to be four times
greater than cutaneous SCC. Little is known regarding the
functional signiﬁcance of YAP and its target genes CCN1 and
CCN2 in BCC. We demonstrate that YAP and both CCN1
and CCN2 are markedly elevated in BCC tumor cells. CCN1
and CCN2 appear to serve a distinct function as YAP effec-
tors; CCN1 regulates keratinocytes growth and survival,
whereas CCN2 likely mediates alterations in stromal ECM
microenvironment.
Materials and Methods
Human Skin Samples
Normal human skin samples were obtained by punch biopsy
(4 mm) from sun-protected hips and buttocks of healthy
adults (age, 40 to 50 years), as previously described.17,18
Completely de-identiﬁed BCC samples were obtained from
the University of Michigan Cutaneous Oncology Unit, Ann
Arbor, MI. Research involving human subjects was approved
by the University of Michigan Institutional Review Board,
and participating subjects provided written informed consent.
Laser Capture Microdissection
For laser capture microdissection (LCM), 15 mm skin sam-
ples embedded in optimal cutting temperature were sectioned
and stained with H&E, and normal epidermis and cancer
cell islands were captured by LCM (Leica ASLMD system;
Leica Microsystems, Wetzlar, Germany), as previously
described.19 Total RNA was prepared from LCM-captured
tissues using a commercial kit (RNeasy Micro kit; Qiagen,
Chatsworth, CA). The quality and quantity of total RNA
were determined by using the Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA).
Immunohistology
Immunohistology was performed as previously described.20
Brieﬂy, skin samples embedded in optimum cutting tempera-
ture were sectioned (7 mm), ﬁxed in 2% paraformaldehyde,
permeabilized with 0.5% Triton X-100 in PBS, blocked with
rabbit serum (5% in PBS), and incubated for 1 hour at room
temperature with YAP, CCN1, or CCN2 primary antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA), followed by
incubation with secondary antibody for 1 hour at room tem-
perature. After staining, the slides were examined using a
digital imaging microscope (Zeiss, Oberkochen, Germany).
Speciﬁcity of staining was determined by substituting isotype-
control immunoglobulin (mouse IgG2a) for the primary anti-
bodies. No detectable staining was observed with isotype
controls (Supplemental Figure S1).938Cell Culture
Human primary keratinocytes were obtained from Cascade
Biologics Inc. (Portland, OR). Adult human primary dermal
ﬁbroblastswere prepared frompunch biopsies of normal adult
buttock skin (age, 21 to 55 years), as previously described.21
Keratinocytes were maintained in EpiLife medium (Life
Technologies, Grand Island, NY) supplemented with kerati-
nocyte growth supplement. Dermal ﬁbroblasts were main-
tained inDulbecco’smodiﬁed Eagle’smedium supplemented
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA).
EpiLife medium and Dulbecco’s modiﬁed Eagle’s medium
were supplemented with 100 U/mL penicillin and 100 mg/mL
streptomycin. Cells were cultured in a humidiﬁed incubator
with 5% CO2 at 37C. Cells were plated at 70% to 80%
conﬂuence, and used 1 day after plating.Human keratinocytes
were transfected with indicated siRNAs and CCN1 or CCN2
expression vectors. Six days after transfection, cultures were
imaged (phase-contract microscopy), and cell numbers
determined by hemocytometer.
RNA Isolation and Quantitative Real-Time RT-PCR
Total RNA was extracted using TRizol reagent (Invitrogen)
or RNeasy micro kit (Qiagen, Gaithersburg, MD). The
cDNA for PCR templates was prepared by reverse tran-
scription of 100 ng total RNA using the Taqman Reverse
Transcription kit (Applied Biosystems, Carlsbad, CA).
Real-time PCR was performed on a 7300 Sequence Detector
(Applied Biosystems) using Taqman Universal PCR Master
Mix Reagents (Applied Biosystems). YAP real-time PCR
primers were designed and purchased from Sigma (St. Louis,
MO): sense primer 50-AGCAGGATGGTGGGACTCAAA-
AT-30; antisense primer 50-AGGTGCCACTGTTAAGGA-
AAGGAT-30. CCN1, CCN2, and 36B4 primer sequences
have been previously described.13 Target gene mRNA ex-
pression levels were normalized to the housekeeping gene
36B4 as an internal control for quantiﬁcation.
Adeno-X Expression Vector Construction and Infection
CCN2 cDNA was ampliﬁed by PCR and gel puriﬁed PCR
product was subcloned into a TA Cloning vector (pCR2.1;
Invitrogen). Puriﬁed pCR2.1 DNA was digested with re-
striction enzymes, and the excised inserts were gel puriﬁed
and ligated into pShuttle. CCN2 pShuttle plasmids were
used to generate the Adeno-X expression vector using the
Adeno-X Expression System (Clontech Laboratories, Inc.,
Temecula, CA) according to the manufacturer’s protocol.
All constructs were subjected to restriction enzyme diges-
tion analysis and nucleotide sequencing to verify correct
sequence and orientation. Adenoviruses were ampliﬁed by
infection of HEK-293FT cells and puriﬁed by sucrose
gradient centrifugation. Cells were infected with control
adenovirus or CCN2 adenovirus at a multiplicity of infec-
tion of 100 plaque-forming units per cell.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 YAPprotein expression and localization in normal human skin and
BCC. Skin sections were immunostained with mouse anti-YAP. A: YAP protein
immunostaining in normal interfollicular skin. B: Normal skin hair. C: Basal cell
carcinoma (BCC). D: Epidermis adjacent to BCC. Representative image from 6
(A), 3 (B), 12 (C), and5 (D) individuals. Isotype control antibody (mouse IgG2a)
immunohistochemical staining in normal skin, BCC, and epidermis adjacent to
BCC were negative (Supplemental Figure S3). Scale bars: 100 mm (AeD).
YAP and CCN1/CCN2 Proteins in BCCTransfection
CCN1 cDNA was ampliﬁed by PCR and gel puriﬁed
PCR product was cloned into expression vector (pCR3.1;Figure 2 YAP target genes CCN1 and CCN2 co-localize with YAP and are up-re
row), and YAP and CCN2 (bottom row), in BCC tumor islands. DAPI staining reveals
and adjacent normal epidermis were obtained by laser capture microdissection, a
(BeD). YAP (B), CCN1 (C), and CCN2 (D) mRNA levels were quantiﬁed by real-t
housekeeping gene 36B4 for quantiﬁcation. Data are means  SEM. N Z 6. *P <
The American Journal of Pathology - ajp.amjpathol.orgInvitrogen).22 YAP siRNA (50-GACAUCUUCUGGUCA-
GAGA-30), was designed and purchased from Sigma. CCN1
and CCN2 siRNAs have been previously described.13,23
CCN1 expression vector and siRNAs were transiently
transfected into human skin keratinocytes by electroporation
(Amaxa Nucleofector, Koeln, Germany), and analysis was
performed after two days transfection.
Western Blot Analysis
Proteins were prepared from skin tissue or cells and equal
amounts of protein (approximately 50 mg per lane) were
analyzed by resolving on 10%SDS-PAGE.The SDSgelswere
transferred to the polyvinylidene diﬂuoridemembrane, and the
membranes were blockedwith 0.1%Tween 20 in PBS (PBST)
containing 5% nonfat milk for 1 hour at room temperature.
Primary antibodies [YAP, SC-101199; CCN1, SC-13100;
CCN2, SC-14939; COL-1, SC-8782; FN, SC-18827; aSMA,
SC-53015 (Santa Cruz Biotechnology) and b-actin, A5441
(Sigma)] were incubated with the polyvinylidene diﬂuoride
membrane for 1 hour at room temperature, after which mem-
branes were washed three times with PBST solution and
incubated with appropriate secondary antibodies for 1 hour at
room temperature. After washing the membranes three times
with PBST, they were developed with Vistra ECF Western
blotting system, (GEHealthcare, Piscataway,NJ) following the
manufacturer’s protocol. The membranes were scanned with agulated in BCC. A: Co-immunoﬂuorescence staining of YAP and CCN1 (top
cell nuclei. Images are representative of ﬁve individuals. BCC tumor islands
nd total RNA was extracted from captured tissue (Supplemental Figure S2)
ime RT-PCR. Target gene mRNA levels were normalized to internal control
0.05. Scale bars: 100 mm (A).
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Figure 3 YAP regulates keratinocyte proliferation
through CCN1, but not CCN2. Human keratinocytes were
transfected with indicated expression vectors. YAP and
CCN1 (A), and YAP and CCN2 (B), protein levels were
determined by Western blot analysis (N Z 3). CeE:
Keratinocyte proliferation was determined 4 days after
addition of indicated siRNAs and expression vectors.
Results are means  SEM. *P < 0.05. Original magni-
ﬁcation,100 (C and D).
Quan et alSTORMMolecular Imager (Molecular Dynamics, Sunnyvale,
CA), the ﬂuorescence intensities of each band were quantiﬁed
by ImageQuant (GEHealthcare), andwere normalizedusingb-
actin as a marker for equal protein loading.
AFM Imaging
The mechanical properties of normal dermis and BCC
stroma were measured by atomic force microscopy (AFM)
using previously established techniques in our laboratory
with minor modiﬁcations.24 Brieﬂy, 20 mm cryosections
of BCC tissues were mounted on microscope glass slides
(25  75  1.0 mm; Fisher Scientiﬁc, Pittsburgh, PA), and
allowed to air dry for at least 48 hours before AFM analysis.
Tissue stiffness was measured by Dimension Icon AFM
system (Bruker-AXS, Santa Barbara, CA) using PeakForce
Quantitative NanoMechanics mode using a silicon AFM
probe (NSC15/AIBS, MikroMasch, San Jose, CA). AFM
was conducted at the Electron Microbeam Analysis Labo-
ratory, University of Michigan College of Engineering, Ann
Arbor, MI, and was analyzed using Nanoscope Analysis
software version 120R1sr3 (Bruker-AXS).
Statistical Analysis
Data are expressed as means  SEM. Student’s t-test was
used to evaluate the statistical differences among the groups.940All P values are two-tailed, and values <0.05 were con-
sidered statistically signiﬁcant.
Results
YAP Protein Expression and Localization in Normal
Human Skin and BCC
First we investigated the expression of YAP protein in normal
adult human skin. YAP protein expression was detectable in
the basal layer of the interfollicular epidermis (Figure 1A) and
outer root sheath of the hair follicle (Figure 1B). The majority
of YAP protein was localized within the cytoplasm of
epidermal keratinocytes (Figure 1A). YAP was primarily
localized in the nucleus in keratinocytes in the outer root
sheath (Figure 1B). YAP staining in the dermis was not
readily apparent (Figure 1, A and B). Interestingly, YAP was
strongly expressed in tumor cell islands in BCC (Figure 1C).
YAP was present in both nuclei and cytoplasm of cells
throughout BCC islands, suggesting aberrant regulation of
YAP expression and activity. YAP expression in epidermis
adjacent to BCCwas limited to the basal layer, as observed in
normal adult skin (Figure 1D and Supplemental Figure S2A).
Based on Western blot analysis, YAP protein levels were
approximately 10-fold greater in BCC tumor islands com-
pared to epidermis (Supplemental Figure S2B). BCC speci-
mens from 12 patients were examined and all displayedajp.amjpathol.org - The American Journal of Pathology
Figure 4 A: YAP target gene CCN2 promotes stroma ﬁbroblast activa-
tion and ECM remodeling. Immunostaining of indicated proteins in normal
human dermis and BCC stroma. Images are representative of six individuals.
Arrows indicate positive staining (red) in stroma surrounding BCC tumor
islands. B: Stiffness of normal dermis and BCC stroma was determined by
atomic force microscopy. Results are means  SEM (NZ 8). C: Human skin
dermal ﬁbroblasts were transfected with control (CTRL) or CCN2 expression
vector, and indicated protein levels were determined by Western blot
analysis (N Z 3). *P < 0.05. Scale bars: 50 mm (A).
YAP and CCN1/CCN2 Proteins in BCCsubstantial tumor island YAP staining. BCC stroma was
mostly negative for YAP staining.
YAP Target Genes CCN1 and CCN2 Co-Localize with YAP
and Are Up-Regulated in BCC
The products of YAP-regulated genes CCN1 and CCN2 co-
localized with YAP protein in tumor cells in BCC islands
(Figure 2A). To quantify mRNA levels, BCC islands and
normal epidermis were isolated by LCM and analyzed by
real-time RT-PCR (Supplemental Figure S3). YAP mRNA
expression was elevated approximately 2.7-fold in LCM-
captured BCC tumor islands (Figure 2B). Additionally,
CCN1 mRNA (Figure 2C) and CCN2 mRNA (Figure 2D)
were elevated 28-fold and 56-fold, respectively, in LCM-
captured BCC, compared to normal epidermis.
YAP Regulates Keratinocyte Proliferation through CCN1
But Not CCN2
Although both CCN1 and CCN2 are generally recognized as
prominent YAP target genes, their roles in mediating YAP
function are poorly understood. To gain insight into the
functionality of elevated YAP and it target genes CCN1 and
CCN2 in BCC, we conducted loss- and gain-of-function
studies in primary human epidermal keratinocytes. Knock-
down of YAP expression by siRNA signiﬁcantly reduced
expression ofCCN1 (Figure 3A) andCCN2 (Figure 3B).YAP
knockdown resulted in near complete loss of keratinocyte
proliferation, determined by cell number 4 days after knock-
down (Figure 3, C and D). Furthermore, at 5 days after
YAP knockdown, the cell number decreased, indicating that
YAP depletion was detrimental to keratinocyte survival
(Supplemental Figure S4). To investigate the role of CCN1
and CCN2 in YAP-mediated keratinocyte growth control,
CCN1 (Figure 3A) or CCN2 (Figure 3B) was restored in
YAP knockdown cells. Restoration of CCN1 expression
(Figure 3C), but not the restoration of CCN2 expression
(Figure 3D), markedly rescued keratinocyte proliferation and
survival inYAP knockdown cells. These differential effects of
YAP effectors on keratinocyte proliferation were conﬁrmed
by knockdown studies. Knockdown of CCN1, but not CCN2,
signiﬁcantly reduced keratinocyte proliferation (Figure 3E).
These data indicate that CCN1, but not CCN2, plays a key role
in mediating YAP regulation of keratinocyte proliferation and
survival.
YAP Target Gene CCN2 Promotes Stroma Fibroblast
Activation and ECM Remodeling
CCN2 is known to regulate ECM production in connective
tissue.14,25,26 CCN2 is markedly elevated in numerous
ﬁbrotic disorders, where it is believed to stimulate excessive
deposition of collagen and other ECM proteins, the hall-
mark of ﬁbrosis.26e28 It is likely, therefore, that elevated
production of CCN2 by BCC tumor cells impacts theThe American Journal of Pathology - ajp.amjpathol.orgfunction and composition of the tumor stromal microenvi-
ronment. In support of this possibility, we observed that
BCC stromal cells adjacent to BCC tumor cell islands
expressed high levels of CCN2 target gene products,
including the major structural proteins type I collagen and
ﬁbronectin, and the myoﬁbroblast marker, a-smooth muscle
actin, compared to normal human skin dermis (Figure 4A).
These alterations were associated with increased stiffness of
the tumor stroma ECM, as measured by atomic force mi-
croscopy (Figure 4B). Furthermore, expression of CCN2 in
adult human dermal ﬁbroblasts resulted in increased levels
of type I collagen, ﬁbronectin, and a-smooth muscle pro-
teins (Figure 4C). These data suggest that secretion of
elevated CCN2, by BCC tumor cells, remodels the stromal
ECM microenvironment through paracrine signaling.Discussion
In normal adult human skin, YAP protein expression is
detectable in the basal layer of the interfollicular epidermis
and outer root sheath of the hair follicle. This restricted
localization of YAP in keratinocytes that possess prolifera-
tive potential is consistent with YAP function in promoting
epidermal proliferation and maintenance of stem cell pop-
ulations.8,16 YAP has been identiﬁed as an oncogene and its
overexpression has been linked to tumorigenesis in various
human cancers.3,5,6 Our ﬁndings indicate that YAP and its
downstream transcriptional targets CCN1 and CCN2 are
markedly elevated in keratinocytes in human skin BCC
tumor islands.941
Quan et alBoth CCN1 and CCN2 are well recognized as prominent
YAP target genes, however, their roles in mediating YAP
function are poorly understood. Our data indicate that
up-regulation of YAP in BCC impacts both aberrant kera-
tinocyte proliferation, via CCN1, and tumor stroma cell
activation and stroma remodeling, via CCN2.
Emerging data demonstrate that tumor stroma is an active
and critical participant in tumor formation and mainte-
nance.9,29 For example, elevated production of ECM com-
ponents, such as collagen and ﬁbronectin, results in
increased stromal ECM stiffness, which is directly impli-
cated in promoting tumor cell proliferation and cancer
progression.30,31 Recent studies demonstrate that YAP ac-
tivity is positively regulated by increased ECM stiffness and
cytoskeletal tension.4,32,33 Interestingly, our work suggests
that YAP promotes ECM stiffness in BCC through up-
regulation of its target gene CCN2. Therefore, up-
regulation of CCN2 may participate in a positive feedback
loop in which YAP-induced CCN2 promotes ECM stiff-
ness, which further activated YAP. These data provide
important new insight into the role of YAP in tumorigenesis
by regulating tumor microenvironment.
Taken together, our data demonstrate that in normal skin,
YAP is detectable in keratinocytes that reside in prolifera-
tive regions of the epidermis and hair follicle, supporting a
role of YAP in promoting epidermal cell growth. In BCC,
YAP and its downstream targets CCN1 and CCN2 are
markedly elevated in tumor islands. We propose that YAP
contributes to BCC formation through up-regulation of
CCN1 and CCN2, which promote keratinocyte growth and
survival, and stromal cell activation and ECM remodeling,
respectively. Targeting YAP and/or CCN1 and CCN2 may
provide clinical beneﬁt in BCC and other cancers in which
YAP is elevated.
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